Difference between revisions of "CNS5:Diffuse leptomeningeal glioneuronal tumour"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[checked revision][checked revision]
Line 1: Line 1:
−
pending
+
{{Under Construction}}
 +
==Primary Author(s)*==
 +
 
 +
Put your text here (Example: Jane Smith, PhD, Institute of Genomics)
 +
 
 +
__TOC__
 +
 
 +
==Cancer Category/Type==
 +
 
 +
Put your text here
 +
 
 +
==Cancer Sub-Classification / Subtype==
 +
 
 +
Put your text here
 +
 
 +
==Definition / Description of Disease==
 +
 
 +
Put your text here
 +
 
 +
==Synonyms / Terminology==
 +
 
 +
Put your text here
 +
 
 +
==Epidemiology / Prevalence==
 +
 
 +
Put your text here
 +
 
 +
==Clinical Features==
 +
 
 +
Put your text here
 +
 
 +
==Sites of Involvement==
 +
 
 +
Put your text here
 +
 
 +
==Morphologic Features==
 +
 
 +
Put your text here
 +
 
 +
==Immunophenotype==
 +
 
 +
Put your text here and/or fill in the table
 +
 
 +
{| class="wikitable sortable"
 +
|-
 +
!Finding!!Marker
 +
|-
 +
|Positive (universal)||EXAMPLE CD1
 +
|-
 +
|Positive (subset)||EXAMPLE CD2
 +
|-
 +
|Negative (universal)||EXAMPLE CD3
 +
|-
 +
|Negative (subset)||EXAMPLE CD4
 +
|}
 +
 
 +
==Chromosomal Rearrangements (Gene Fusions)==
 +
 
 +
Put your text here and/or fill in the table
 +
 
 +
{| class="wikitable sortable"
 +
|-
 +
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
 +
|-
 +
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5%
 +
|-
 +
|EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5%
 +
|}
 +
 +
==Characteristic Chromosomal Aberrations / Patterns==
 +
 
 +
Put your text here
 +
 
 +
==Genomic Gain/Loss/LOH==
 +
 
 +
Put your text here and/or fill in the table
 +
 
 +
{| class="wikitable sortable"
 +
|-
 +
!Chromosome Number!!Gain/Loss/Amp/LOH!!Region
 +
|-
 +
|EXAMPLE 8||EXAMPLE Gain||EXAMPLE chr8:0-1000000
 +
|-
 +
|EXAMPLE 7||EXAMPLE Loss||EXAMPLE chr7:0-1000000
 +
|}
 +
 +
==Gene Mutations (SNV/INDEL)==
 +
 
 +
Put your text here and/or fill in the tables
 +
 
 +
{| class="wikitable sortable"
 +
|-
 +
!Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)
 +
|-
 +
|EXAMPLE TP53||EXAMPLE R273H||EXAMPLE Tumor Suppressor||EXAMPLE LOF||EXAMPLE 20%
 +
|}
 +
 +
===Other Mutations===
 +
{| class="wikitable sortable"
 +
|-
 +
!Type!!Gene/Region/Other
 +
|-
 +
|Concomitant Mutations||EXAMPLE IDH1 R123H
 +
|-
 +
|Secondary Mutations||EXAMPLE Trisomy 7
 +
|-
 +
|Mutually Exclusive||EXAMPLE EGFR Amplification
 +
|}
 +
 
 +
==Epigenomics (Methylation)==
 +
 
 +
Put your text here
 +
 
 +
==Genes and Main Pathways Involved==
 +
 
 +
Put your text here
 +
 
 +
==Diagnostic Testing Methods==
 +
 
 +
Put your text here
 +
 
 +
==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)==
 +
 
 +
Diagnosis: Put your text here
 +
 
 +
Prognosis: Put your text here
 +
 
 +
Therapeutic: Put your text here
 +
 
 +
==Familial Forms==
 +
 
 +
Put your text here
 +
 
 +
==Other Information==
 +
 
 +
Put your text here
 +
 
 +
==Links==
 +
 
 +
Put your links here (use "Link" icon at top of page)
 +
 
 +
==References==
 +
(use "Cite" icon at top of page)
 +
<references />
 +
===EXAMPLE Book===
 +
 
 +
#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.
 +
 
 +
==Notes==
 +
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

Revision as of 08:56, 11 September 2024

Primary Author(s)*

Put your text here (Example: Jane Smith, PhD, Institute of Genomics)

Cancer Category/Type

Put your text here

Cancer Sub-Classification / Subtype

Put your text here

Definition / Description of Disease

Put your text here

Synonyms / Terminology

Put your text here

Epidemiology / Prevalence

Put your text here

Clinical Features

Put your text here

Sites of Involvement

Put your text here

Morphologic Features

Put your text here

Immunophenotype

Put your text here and/or fill in the table

Finding Marker
Positive (universal) EXAMPLE CD1
Positive (subset) EXAMPLE CD2
Negative (universal) EXAMPLE CD3
Negative (subset) EXAMPLE CD4

Chromosomal Rearrangements (Gene Fusions)

Put your text here and/or fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence
EXAMPLE t(9;22)(q34;q11.2) EXAMPLE 3'ABL1 / 5'BCR EXAMPLE der(22) EXAMPLE 5%
EXAMPLE t(8;21)(q22;q22) EXAMPLE 5'RUNX1 / 3'RUNXT1 EXAMPLE der(8) EXAMPLE 5%

Characteristic Chromosomal Aberrations / Patterns

Put your text here

Genomic Gain/Loss/LOH

Put your text here and/or fill in the table

Chromosome Number Gain/Loss/Amp/LOH Region
EXAMPLE 8 EXAMPLE Gain EXAMPLE chr8:0-1000000
EXAMPLE 7 EXAMPLE Loss EXAMPLE chr7:0-1000000

Gene Mutations (SNV/INDEL)

Put your text here and/or fill in the tables

Gene Mutation Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other)
EXAMPLE TP53 EXAMPLE R273H EXAMPLE Tumor Suppressor EXAMPLE LOF EXAMPLE 20%

Other Mutations

Type Gene/Region/Other
Concomitant Mutations EXAMPLE IDH1 R123H
Secondary Mutations EXAMPLE Trisomy 7
Mutually Exclusive EXAMPLE EGFR Amplification

Epigenomics (Methylation)

Put your text here

Genes and Main Pathways Involved

Put your text here

Diagnostic Testing Methods

Put your text here

Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)

Diagnosis: Put your text here

Prognosis: Put your text here

Therapeutic: Put your text here

Familial Forms

Put your text here

Other Information

Put your text here

Links

Put your links here (use "Link" icon at top of page)

References

(use "Cite" icon at top of page)

EXAMPLE Book

  1. Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

Retrieved from "https://ccga.io/index.php?title=CNS5:Diffuse_leptomeningeal_glioneuronal_tumour&oldid=15431"